Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table
Corresponding Author
Katherine Grosset MBChB
Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Department of Neurology, Southern General Hospital, Glasgow G51 4TFSearch for more papers by this authorFiona Needleman MSc
Department of Clinical Pharmacy, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorGraeme Macphee FRCP
Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorDonald Grosset MD
Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorCorresponding Author
Katherine Grosset MBChB
Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Department of Neurology, Southern General Hospital, Glasgow G51 4TFSearch for more papers by this authorFiona Needleman MSc
Department of Clinical Pharmacy, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorGraeme Macphee FRCP
Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorDonald Grosset MD
Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorAbstract
Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population. © 2004 Movement Disorder Society
References
- 1 Hubble JP. Long-term studies of dopamine agonists. Neurology 2002; 58: S42–S50.
- 2 The Committee on Safety of Medicines (Medicines Control Agency). Fibrotic reactions with pergolide and other ergot-derived dopamine receptor agonists. Curr Probl Pharmacovigilance 2002; 3.
- 3 Benard A, Guenanen H, Tillie-Leblond I, et al. [Drug-induced pleurisy]. Rev Mal Respir 1996; 13: 227–234.
- 4 Shaunak S, Wilkins A, Pilling JB, et al. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999; 66: 79–81.
- 5 Saura J, Aguilar M, Alio J. [Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment]. Neurologia 1991; 6: 331–333.
- 6 Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol 1990; 27: 79–82.
- 7 Geminiani G, Fetoni V, Genitrini S, et al. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord 1996; 11: 495–500.
- 8 Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999; 74: 371–375.
- 9 Kains JP, Hardy JC, Chevalier C, et al. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine. Acta Clin Belg 1990; 45: 306–310.
- 10 Jimenez-Jimenez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995; 18: 277–279.
- 11 Sanchez-Chapado M, Angulo CJ, Guil CM, et al. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease]. Arch Esp Urol 1995; 48: 979–983.
- 12 Kunkler RB, Osborn DE, Abbott RJ. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Br J Urol 1998; 82: 147.
- 13 Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77: 1280–1286.
- 14 The Committee on Safety of Medicines (Medicines Control Agency). Pergolide (Celance) and cardiac valvulopathy. Curr Probl Pharmacovigilance 2003; 7.
- 15 Van Camp G, Flamez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859–861.
- 16 Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci 1999; 26(Suppl. 2): S27–S33.
- 17 Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–1491.
- 18 Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931–1938.
- 19 Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 1999; 52: 1227–1229.
- 20 Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. J Neural Transm 1999; 106: 925–929.
- 21 Council of the European Communities. European Commission Council Directive. Brussels European Commission. 1992;92/27/EEC, OJ Number L:113–118.
- 22 Hanna PA, Ratkos L, Ondo WG, et al. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 2001; 108: 63–70.
- 23 Goetz CG, Shannon KM, Tanner CM, et al. Agonist substitution in advanced Parkinson's disease. Neurology 1989; 39: 1121–1122.
- 24 European Commission. EC Pharmaceutical Committee. A guideline on the reliability of the label and package leaflet of medicinal products for human use. 1998.
- 25 Gimenez-Roldan S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 2001; 24: 346–351.
